(Anchorage, AK) – The State of Alaska has joined with other states and the federal government to reach an agreement with Gilead Sciences, Inc. (“Gilead”) to settle allegations that the company paid kickbacks to providers to improperly promote its HIV drugs: Stribild, Genvoya, Complera, Odefsey, Descovy, and Biktarvy (the “Gilead HIV Drugs”).
“Kickback schemes drain Medicaid dollars and put patients at risk,” said Alaska Attorney General Stephen Cox. “Our Medicaid Fraud Control Unit will hold accountable anyone who abuses these programs, and I know from my DOJ experience that the best results come when states and the federal government work together. We’ll continue partnering with our federal colleagues to go after fraud against both state and federal programs.”
Gilead, a California-based large pharmaceutical company, which among other things, developed, manufactured, and sold drugs for the treatment of infectious diseases, including HIV/AIDS, will pay the states and the federal government $202 million. $49,045,600.00 of the payment will go to Medicaid programs to resolve civil allegations that Gilead’s unlawful promotion of the Gilead HIV Drugs caused false claims to be submitted to the government health care programs. Of that amount, Alaska will receive $20,203.14 in restitution and other recoveries.
Specifically, the settlement will resolve allegations that from Jan. 1, 2011, through Nov. 17, 2017, Gilead offered and paid remuneration in the form of honoraria payments,...
Amid the row over ‘cough syrup deaths’, the Press Information Bureau (PIB)'s fact-check arm on Monday, busted a video claiming that Dextromethorphan Hydrobromide component in cough syrups has been...